Genvor's Antifungal Peptide Validated in Publication

- Aflatoxin contamination, the problem Genvor's technology addresses, can cause annual economic losses to the U.S. corn industry ranging from $52.1 million to $1.68 billion, depending on the severity of contamination in a given year. - The AGM182 peptide was designed using Genvor's BioCypher™ Algorithm, an AI-driven platform, and is derived from tachyplesin, a peptide found in the blood of the horseshoe crab. In vitro studies showed AGM182 has a five-fold increase in antifungal activity against *Aspergillus flavus* compared to the original tachyplesin peptide. - This validation builds on a long-standing partnership; Genvor has a Cooperative Research and Development Agreement (CRADA) with the USDA that has been active for over seven years. The patent for transgenic corn using the AGM182 peptide is co-assigned to both Genvor and the USDA. - Genvor is a publicly traded company on the OTCQB market under the ticker GNVR. The company, formerly known as Allure Worldwide, Inc., changed its name to Genvor Incorporated in June 2022. - Beyond transgenic seed traits, Genvor is also developing its peptide technology for use in topical biological sprays and as nutritional enhancement peptides to improve nutrient uptake in plants. - The research demonstrated that the AGM182 peptide is also effective against *Fusarium* species, another fungus that contributes to yield loss and grain contamination. The trials showed no adverse effects on the corn's growth or yield. - Aflatoxins are considered one of the most toxic and carcinogenic mycotoxins and pose a serious threat to human and animal health, linked to liver cancer. Their prevalence is higher in warm, humid climates, and they can contaminate milk if consumed by dairy animals.